AU2006220918A1 - Treatment of amyotrophic lateral sclerosis with norethindrone and anal0gues6 - Google Patents

Treatment of amyotrophic lateral sclerosis with norethindrone and anal0gues6 Download PDF

Info

Publication number
AU2006220918A1
AU2006220918A1 AU2006220918A AU2006220918A AU2006220918A1 AU 2006220918 A1 AU2006220918 A1 AU 2006220918A1 AU 2006220918 A AU2006220918 A AU 2006220918A AU 2006220918 A AU2006220918 A AU 2006220918A AU 2006220918 A1 AU2006220918 A1 AU 2006220918A1
Authority
AU
Australia
Prior art keywords
sod
progesterone receptor
protein
norethindrone
als
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006220918A
Other languages
English (en)
Inventor
Daniel Benjamin
Sean Scott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ALSGEN Inc
Original Assignee
ALSGEN Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ALSGEN Inc filed Critical ALSGEN Inc
Publication of AU2006220918A1 publication Critical patent/AU2006220918A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2006220918A 2005-03-04 2006-03-01 Treatment of amyotrophic lateral sclerosis with norethindrone and anal0gues6 Abandoned AU2006220918A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65863005P 2005-03-04 2005-03-04
US60/658,630 2005-03-04
PCT/US2006/007253 WO2006096404A2 (en) 2005-03-04 2006-03-01 Treatment of amyotrophic lateral sclerosis with norethindrone and anal0gues

Publications (1)

Publication Number Publication Date
AU2006220918A1 true AU2006220918A1 (en) 2006-09-14

Family

ID=36825491

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006220918A Abandoned AU2006220918A1 (en) 2005-03-04 2006-03-01 Treatment of amyotrophic lateral sclerosis with norethindrone and anal0gues6

Country Status (7)

Country Link
US (2) US20060205704A1 (enExample)
EP (1) EP1861107A2 (enExample)
JP (1) JP2008536808A (enExample)
CN (1) CN101232888A (enExample)
AU (1) AU2006220918A1 (enExample)
CA (1) CA2600064A1 (enExample)
WO (1) WO2006096404A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101184493A (zh) * 2005-03-04 2008-05-21 阿尔斯根公司 用乙胺嘧啶及类似物治疗肌萎缩性侧索硬化
US20100028360A1 (en) * 2008-07-26 2010-02-04 Craig Stephen Atwood Methods for the modulation of brain progestagen signaling in the prevention and treatment of neurological disorders and neurodegenerative diseases
EP2320912B1 (en) * 2008-08-05 2015-01-14 University College Cork-National University of Ireland, Cork Treatment of retinal degeneration
US9446051B2 (en) 2009-10-19 2016-09-20 The Population Council, Inc. Neuroprotection and myelin repair using nestorone®
BR112012009306A2 (pt) * 2009-10-19 2016-06-07 Population Coucil Inc método para regeneração de mielina em um paciente
CA2836388A1 (en) * 2012-12-21 2014-06-21 The Population Council, Inc. Neuroprotection and myelin repair using st-1435

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916910A (en) * 1997-06-04 1999-06-29 Medinox, Inc. Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore
US20050019915A1 (en) * 2001-06-21 2005-01-27 Bennett C. Frank Antisense modulation of superoxide dismutase 1, soluble expression
EP1611238B1 (en) * 2003-02-26 2009-06-17 The John Hopkins University Glutamate transport modulatory compounds and methods
CN101184493A (zh) * 2005-03-04 2008-05-21 阿尔斯根公司 用乙胺嘧啶及类似物治疗肌萎缩性侧索硬化

Also Published As

Publication number Publication date
WO2006096404A3 (en) 2007-06-07
JP2008536808A (ja) 2008-09-11
EP1861107A2 (en) 2007-12-05
CA2600064A1 (en) 2006-09-14
WO2006096404A2 (en) 2006-09-14
WO2006096404A8 (en) 2008-03-06
US20060205704A1 (en) 2006-09-14
US20090062245A1 (en) 2009-03-05
CN101232888A (zh) 2008-07-30

Similar Documents

Publication Publication Date Title
Lan et al. Update on the neuroprotective effect of estrogen receptor alpha against Alzheimer's disease
Gold et al. Estrogen treatment in multiple sclerosis
Vagnerova et al. Gender and the injured brain
JP6926065B2 (ja) 癌を治療するための方法
Mubarak et al. Synaptic NMDAR activity suppresses FOXO1 expression via a cis-acting FOXO binding site: FOXO1 is a FOXO target gene
Bhasin et al. Age-related changes in the male reproductive system
US20090074795A1 (en) Methods for addressing ocular diseases through interference with the wnt signaling pathway
US20190381047A1 (en) Methods for treatment of retinal disease by photoreceptor gene expression modulation
US20090062245A1 (en) Modulation of Neurodegenerative Diseases Through The Progesterone Receptor
Borner et al. Brainstem GLP-1 signalling contributes to cancer anorexia-cachexia syndrome in the rat
KR20120027353A (ko) Ｃｍｔ 및 관련 장애를 치료하기 위한 신규 조성물
Feng et al. SGK1-mediated fibronectin formation in diabetic nephropathy
JP2004525135A (ja) 糖質コルチコイドレセプター特異的アンタゴニストを使用するストレス障害を処置するための方法
US20060211645A1 (en) Modulation of neurodegenerative diseases
El-Lakany et al. Ovariectomy provokes inflammatory and cardiovascular effects of endotoxemia in rats: Dissimilar benefits of hormonal supplements
Alsadi Clinical features of PCOS
Hu et al. Exogenous progesterone: a potential therapeutic candidate in CNS injury and neurodegeneration
Takemoto et al. An herbal medicine, Go-sha-jinki-gan (GJG), increases muscle weight in severe muscle dystrophy model mice
JP2019524805A (ja) 髄鞘再生療法
US20060211673A1 (en) Modulation of neurodegenerative diseases through the estrogen receptor
WO2002087552A2 (en) Androgen-mediated neuroprotection and uses thereof
US20100286043A1 (en) Use of neuregulin-1 in reducing brain damage
Cara Role of Androgen Receptor in Hypothalamic Regulation of Metabolism and Reproduction
JP2017197436A (ja) 神経筋接合部形成促進薬
Orozco-Suárez et al. Epilepsy: Experimental and Human Studies

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period